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ABSTRACT 
Objective: In this study, biodegradable Chitosan Ascorbate Microsphere (CAMs) and mannosylated chitosan ascorbate microsphere (m-CAMs) 
prepared for targeting towards alveolar macrophages to treatment of pulmonary tuberculosis.   
Significance: Ascorbic acid is an antioxidant and reported killing effect on mycobacterium by induces fenton reaction. This study enlightens the 
possible benefits of adding antioxidant properties of ascorbic acid with chitosan microsphere to an anti-tuberculosis regimen and 
mannosylation of microsphere significantly induce the targetability of antitubercular drug to alveolar macrophages.  
Methods: CAMs prepared by firstly salification of chitosan by ascorbic acid then ionic gelation with STPP and m-CAMs prepared by incubation 
method and purified for further studies. The physicochemical, in vitro and in vivo characterizations of both formulations were carried out.  
Results: The size of microspheres (both CAMs and m-CAMs) were found to be in range of 3.40-4.81µm. Evident changes were observed in 
crystallinity and structure of both carrier systems and depicted by Fourier transform infrared (FTIR), Differential scanning calorimetry (DSC) 
and X-ray diffraction (XRD) studies. In vitro lung deposition study of microspheres showed favourable aerodynamic properties for deep lung 
delivery (MMAD 2.0- 3.8 μm) and, thus, show potential for an application as inhalable tuberculosis therapy. The drug release showed the 
biphasic pattern of release, i.e., initial burst (30-45% up to 8 h) followed by a slower sustained release pattern (more than 80% up to 72 h) in 
both simulated lung fluids. Optimized formulations exhibited lower cytotoxicity and bio distribution studies demonstrated the efficiency of m-
CAMs for spatial delivery of INH to alveolar tissues. CAMs and m-CAMs evidenced minor cytotoxicity on lung epithelial cells (A549 cell lines).  
Conclusion: m-CAMs thus has a promising potential to be explore as an effective carrier system for delivery of antitubercular drugs regimen.  
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INTRODUCTION 
Worldwide, Tuberculosis (TB) is one of the top 10 causes of 
death and the leading cause from a single infectious agent 
(above HIV/AIDS) 1. The World Health Organization has set a 
deadline to end the TB epidemic by 2035, which includes a 
90-95% reduction in TB incidence and in the number of TB-
related deaths 2, 3. The causative agent Mycobacterium 
tuberculosis (MTB), an intracellular parasitic pathogen 
resides in alveolar Macrophage (AM) that mainly affects the 
respiratory tract. 
The current treatment regimen for TB consists of 
administering the drugs via oral or parenteral routes which 
remain challenging for clinicians because of high systemic 
delivery of single or multiple drug associated with various 
problems i.e. patient incompliance, toxic effects and 
development of resistance due to high systemic exposure 4, 5. 
Due to poor pulmonary tissue diffusion of the administered 
drugs, the drug concentration achieved in the lungs is in the 
sub-therapeutic range, when given by these conventional 
routes. Thus, the situation has come to a point where the 
development of novel intervention strategies is urgently 
needed. 
A well-explored way to deliver anti-TB drugs is via the 
pulmonary route by which high concentrations can be 
achieved in the lungs which would be coupled with low 
systemic bio-distribution and toxicity. The ways of direct 
pulmonary administration of drugs include nebulization of 
drug solutions or particulate formulations including 
nanoparticles, liposomes and microparticles. 
In this regard, inhalable therapy has great potential, allowing 
the direct administration of drugs to the infection site. This 
approach would potentially enable reducing the dosing 
frequency and shorten the treatment duration, thereby 
avoiding severe systemic side effects and improving patient 
compliance. Implementing this therapeutic strategy requires 
the design of antitubercular inhalable formulations with 
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suitable aerodynamic properties to reach the alveoli, where 
the alveolar macrophages infected with M. tuberculosis are 
located. 
Substantial research has been done to develop alveolar 
macrophage targeting for pulmonary delivery wherein the 
drugs are entrapped in polymers, copolymers and lipids. 
Such formulations include microparticles 6-8, nanoparticles 5, 
9, solid lipid nanoparticles 2 etc.  
Chitosan is deacetylated derivative of chitin, is widely 
distributed in nature and has been widely used as a drug 
carrier offering advantages of mucoadhesivity, good 
biocompatibility, non-immunogenicity, and non-toxicity 10, 11. 
Over the years, micro and nano-particulate carrier systems 
composed of chitosan polymer have widely been studied for 
the delivery of drugs and bio-macromolecules. It displays 
unique property of binding to the cell membrane which is 
manifested as enhancement in its cellular uptake and 
transfection efficiency.  
Ascorbic acid is a well-known antioxidant present in cells 
and plasma of humans. Its beneficial effect and antioxidant 
properties have been widely studied. But due to unstability, 
get oxidised to dehydroascorbic acid in light air and 
temperature.  To increase the stability of Ascorbic acid 
various derivatives have been synthesized, including the 
metal salts (Na, Ca salts), ethers, esters and the 
polysaccharide derivatives 12. Here chitosan properties 
combined with ascorbic acid by formation of chitosan 
ascorbate, a soluble ketimine formed due to salification of 
chitosan has shown increased stability, antioxidant 
properties, permeability and adhesiveness. Applications of 
chitosan properties with ascorbic acid applied previously in 
various field wound healing 13, vaginal delivery of peptides 
14.  
Interestingly, one finding has demonstrated that ascorbic 
acid sterilized he culture of drug susceptible and drug 
resistant mycobacterium tuberculosis the generation of 
highly reactive hydroxyl radicals via the Fenton reaction 15. 
Recently, it has been investigated that ascorbic acid had no 
activity by itself in M. tuberculosis-infected mice, the 
combination of it with the first line TB drugs reduced the 
bacterial burden in the lungs of M. tuberculosis-infected mice 
faster than drug alone 16. 
To the best of our knowledge, we believe so far there are no 
reports on the synthesis of chitosan ascorbate microspheres 
for pulmonary delivery of antitubercular drugs. In view of its 
unique properties reported earlier with little knowledge 
about the nano form of this compounds characteristics 17, the 
present study aims to investigate the microspherical 
formation, its physiochemical properties, antioxidant 
efficacy, in-vitro drug release and lung deposition study, 
cytotoxicity on A549 cell line. We hypothesize that this 
proposed approach would surmount precise toxicity 
limitations and be a utile choice of carrier system based drug 
delivery with therapeutic properties. 
MATERIALS AND METHODS 
Isoniazid (purity˃99%) was received as a gift sample by 
Lupin Ltd, Aurangabad (Maharashtra India). Chitosan have 
degree of deacetylation (80.0-95%), sodium 
tripolyphosphate (STPP), L-Ascorbic acid (99%), FITC Dye 
were purchased from Sigma-Aldrich, India. Methanol and 
Acetonitrile (HPLC grades) was purchased from CDH 
chemicals. DMEM Medium with High Glucose and Fetal 
Bovine Serum (FBS), Penicillin-Streptomycin Solution, FITC 
and MTT were purchased from Sigma Co., Ltd. All the 
chemicals and ingredients utilized for studies were of AR 
grade. Double distilled water was utilized throughout the 
study. 
Preparation of Mannosylated Chitosan Ascorbate 
Microsphere (m-CAMs): 
Mannosylated Chitosan Ascorbate Microspheres (m-CAMs) 
were prepared by a two-step process involving (i) in-situ 
synthesis of Chitosan Ascorbate Microsphere (CAMs) and (ii) 
mannosylation of above prepared CAMs (m-CAMs). 
CAMs were synthesized by modified ionotropic gelation. 1.5 
% (w/v) low molecular weight chitosan powder was added 
to 1.0 M ascorbic acid solution and stirred continuously until 
a clear solution obtained. The solution was allowed to stand 
for 3 h. Then addition of 5 % (w/v) STPP solution at 8 
ml/min flow rate and 800rpm (Multistage magnetic stirrer, 
Velp, Italy) for 30 min. The dropping rate and falling distance 
of STPP solution were kept constant. Then spontaneously 
formed microsphere suspension was kept overnight then 
centrifuge at 5000 rpm for 5 min. The microspheres were 
washed two times with distilled water, laid out on aluminium 
trays, and dried until weight remains constant. INH loaded 
Chitosan Ascorbate microsphere (INH-CAMs) were prepared 
using the procedure just described, except INH (100mg) 
dissolved initially in chitosan solution. Optimization studies 
performed to achieve optimum size of formulation for 
pulmonary delivery of INH [Table 1]. 
 
Table 1: Optimization of formulation variable: 
Formulation  Concentration Particle size 
(µm) 
Zeta potential PDI Entrapment 
Efficiency of INH 
Ascorbic Acid Concentration (M) 0.5 4.01±0.25 20.3±1.1 0.30±0.04 58.14±0.12 
 1.0 3.25±0.14 28.1±1.4 0.53±0.07 61.42±0.20 
 1.5 2.14±0.11 27.4±2.1 0.37±0.03 62.90±0.21 
Chitosan concentration (% w/v) 0.5 1.98±0.78 24.2±2.2 0.67±0.06 60.81±0.14 
 1.5 3.58 ± 0.34 36.2±1.2 0.75±0.03 63.34±0.91 
 2.5 5.66± 0.54 38.5± 3.1 0.71±0.18 59.25±0.40 
STPP concentration (w/v) 1 2.10±0.40 36.2±2.6 0.52±0.16 59.14±0.12 
 5 3.10±0.20 39.4±2.9 0.41± 0.08 62.44±0.22 
 10 4.91±0.51 22.9±1.2 1.02±0.60 56.21±0.32 
Note: All values are expressed as mean± S.D. (n=3) 
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Table 2: Optimization of incubation time during mannosylation: 
Formulation Incubation Time Average size Zeta Potential 
Optimization of incubation time  12 5.81±1.44 -21.1±1.22 
 24 4.10±1.58 -17.54±0.68 
 48 6.47±2.14 -26.87±0.41 
 
Mannosylation was carried out by adopting the method 
describe 18, 19 with certain modification. The coupling of 
mannose to the amine group of chitosan was carried out in 
two steps. In first step, coupling reaction done initially 
where D-mannose (10 µm) was dissolved in 0.1 M sodium 
acetate buffer at pH  4 and 60◦ C for 2 hr resulting in the ring 
opening of mannose molecule. In second step, this solution 
was mixed thoroughly with chitosan microsphere 
synthesized earlier and incubated for 24 hr at room 
temperature. The aldehyde group of ring opened mannose 
reacts with amine group of chitosan, yielding mannosylated 
chitosan and the resulting solution centrifuged at 5000rpm 
and washed thoroughly with distilled water. 
Purification of m-CAMs: Formulation were purified by 
dialyzing against double distilled water in a dialysis tube 
(>900KDa MWCO) for 24 hr to remove any unreacted drug 
and polymer. 
Physico-chemical characterization of carrier system: 
Particle size Analysis and morphological characteristics: 
Particle size was determined by digital photographic 
microscope and Malvern ZetaSizer (Mastersizer X, Malvern 
Instruments Ltd., UK). For determination of particle size, the 
microspheres were suspended in methanol containing 0.1% 
Tween 80 to prevent aggregation, and the mean particle size 
and polydispersity index were determined. For 
determination of zeta potential, the microspheres were 
suspended in de-ionized water and placed in disposable 
polystyrene electrophoretic cells. The total zeta runs were 
100 and the count rate was 250 particles/sec. The 
experiments were performed in triplicate.  
The surface characteristics were studied by scanning 
electron microscope (Model JSM-6390A, JEOL, Japan) from 
5X to 300000X magnifications at the MSME Department, 
MANIT, Bhopal India. The powder sample was sprinkled 
onto the carbon tape affixed on aluminium stubs. The 
aluminium stubs were placed in the vacuum chamber and 
observed for morphological characterization. 
Powder X-ray Diffraction (PXRD) Studies: PXRD were 
determined for drug and drug loaded carrier systems CAMs 
and m-CAMs. Samples were exposed to a monochromatic 
nickel-filtered copper radiation (40 kV, 30 mA) in a wide-
angle X-ray diffractometer (XPERT-PRO system) with 2θ 
angle. 
FTIR Study: Samples were prepared in KBr disc (4 mg 
sample/200 mg KBr) using a hydrostatic press at a force of 
40 psi for 4 min. Each sample was scanned thrice between 
4000 and 400 cm−1at a resolution of 4 cm−1 and averaged for 
that sample and there were three (n = 3) different samples 
scanned. 
Differential scanning calorimetry (DSC): DSC was 
performed for chitosan, ascorbic acid and CAMs using a 
PyrisTM Diamond DSC (PerkinElmer). Accurately weighted 
samples (5±0.1 mg) were used for the analysis, and it was 
sealed in aluminum pans. They were scanned from 50ºC to 
350 ºC at 10 ºC/ min.  
Antioxidant activity assay: Antioxidant activity assay 
performed for chitosan ascorbate microsphere by following 
method 20, 21. Different concentrations of testing samples and 
2 mL of DPPH ethanol solution (180 μmol/L) were incubated 
for 30 min at room temperature. Then, the absorbance of the 
remained DPPH radical was measured at 517 nm against a 
blank. Three replicates for each sample were tested and the 
DPPH-radical scavenging effect was calculated according to 
the following equation: 
                        
                                   
             
      
Where Asample 517 nm is the absorbance of the samples, 
Acontrol 517 nm is the absorbance of the control (DPPH was 
substituted with ethanol), and Ablank 517 nm is the 
absorbance of the blank (samples were substituted with 
distilled water). Pure ascorbic acid solution was used as a 
positive control. 
In-vitro lung deposition study: In-vitro lung deposition 
pattern of formulation determined by an Andersen Cascade 
Impactor (ACI) (Thermofisher Scientific, U.K.) by calculated 
parametrs i.e. percent emitted dose (% ED), mass median 
aerodynamic diameter (MMAD) and fine particle fraction 
(FPF) of various formulations. Optimized formulations 
having higher drug loading were selected for this study and 
accurately weighted amount was mixed with micronized 
lactose at a 1:3 (w/w) ratio and dosed in an eight-stage 
nonviable Anderson cascade impactor. After the completion 
of dosing) % ED, MMAD and FPF were calculated from the 
deposition data using the MMAD calculator for Anderson 
apparatus using a flow rate of 28.3 L/min. The experiment 
was performed in triplicate. 
In-vitro drug release study: Release study of INH were 
independently conducted in two simulated lungs fluids; 
Gamble’s Solution (pH 7.4) and Alveolar Lung Fluid (ALF pH 
4.5) 22, 23. A USP Type II tablet dissolution test apparatus 
(Electrolab, Mumbai, INDIA) was used for in-vitro drug 
release. The stirring speed was kept 150rpm. A dialysis 
membrane (Himedia, molecular weight cut-off >900 kDa) 
was cut into equal pieces of about 6cmX2.5cm and pre-
treated. Equivalent to 5mg each of INH loaded CAMs and m-
CAMs were dispersed in 1ml of PBS pH 7.4 and filled in the 
pre-treated dialysis membrane and sealed with clips. The 
pouch thus formed was attached to the paddles of the 
apparatus using rubber bands wound over the clips. Nine-
hundred millilitres of Gamble’s solution pH 7.4 and Alveolar 
Lung Fluid pH 4.5 (ALF) were used for the study. Samples of 
5ml were drawn and 5ml fresh medium was replaced at each 
time interval 0.5, 1, 2, 4, 6, 8, 16, 24, 48, 72 hr 24. The drug 
was estimated at 262 nm using UV-Visible spectro-
photometer (Model 1800 UV-Visible spectrophotometer, 
Shimadzu, Japan). All the samples were tested in triplicates. 
In-vitro Cell proliferation Assay: 
Cell lines and medium: 
Human non-small cell lung cancer, A549 cell line was 
initially procured from  National Center for Cell Sciences 
(NCCS), Pune, India and then cultured in 95 % air and 5%  
CO2 at 37 ºC using DMEM (Dulbecco’s Modified Eagle’s 
Medium) supplemented with Fetal Bovine serum (FBS 10% 
v/v) and  penicillin (1%v/v). All experiments were 
performed with asynchronous cell populations in 
exponential growth phase (24 h after plating) 25. 
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Cytotoxicity was determined by standard colorimetry based, 
MTT (3-[4, 5 dimethylthiazol-2-yl]-2, 5 diphenyltetra 
zoliumbromide) assay 26. In brief, 5 × 104 A549 cells were 
seeded in 96 well plates allowed to grow for 24 h. A549 cells 
were then exposed continuously to pure INH solution (PBS, 
pH 7.4), CAMs suspension (PBS, pH 7.4), m-CAMs suspension 
(PBS, pH 7.4), INH loaded CAMs and INH loaded m-CAMs at a 
concentration equivalent to 20-100 µg/mL. At 24 h 
treatment period with formulations A549 cells were 
incubated with MTT (0.5 mg/mL) for 4 h at 37◦ C. The cells 
were lysed and the formazan crystals were dissolved by 
using 100 µl of DMSO. The absorbance was read at 570 nm 
by using 630 nm as reference wavelength in ELISA (Enzyme 
linked immunosorbent assay)  
                     
                         
                     
      
Pharmacokinetic study and biodistribution studies: 
Female BALB/c mice (20-30 g) were used to carried out the 
pharmacokinetic and organ biodistribution studies in 
accordance with the protocol approved by the Institutional 
Animal Ethics Committee, under the guidelines compiled by 
CPCSEA (Committee for the purpose of control Supervision 
of Experiments on Animal), Ministry of Culture, Government 
of India and the Local Institutional Animal Ethics Committee 
has approved all the study protocols vide approval no. 
IAEC/VCP/2018/001/2.  
The drug distribution to various organs/tissues after 
intratracheal administration of microspheric formulations 
by aerosolization was performed using a MicroSprayerTM 
aerosoliser (IA-1C; Penn-Century, Philadelphia, PA, USA), 
attached to a high-pressure syringe (FMJ- 250; Penn-
Century). This device is an aerosol generator consisting of a 
sub-miniaturized atomizer located in the tip of a 1.25’ 
stainless steel tube, which is attached to a hand operated, 
high-pressure syringe. Animals were divided into four 
groups (Table 5), each containing six animals (n=6). Group 1 
animals keep as a controlled and animals of group 2 were 
administered with 5 mg INH in 500µl sterilized phosphate 
buffer saline through intra-trachea insillation. Similarly, 
group II and III received both formulations CAMs and m-
CAMs respectively, equivalent to 5 mg drug, dispersed in 
500µl PBS. Following the drug administration, blood was 
collected after 1, 2, 4, 8, 12 and 24 hr through retro orbital 
plexus. Collected blood sample 0.5 ml were centrifuge at 
1000 rpm for 20 min; plasma was separated and filtered 
through membrane filter 0.45 µm.  
Table 5: Selected groups for pharmacokinetic study: 
Formulation Formulations  
Group 1 Controlled 
Group 2 Free INH drug solution 
Group 3 INH loaded CAMs 
Group 4 INH loaded m-CAMs 
 
Drug estimation in plasma was done using a developed high-
performance liquid chromatography (HPLC) technique 27 
and calibration curve was obtained by analyzing pooled 
blank plasma spiked with known amount of drug. The 
plasma concentration versus time data, obtained after 
intratracheal instillation of free drugs and different 
formulations were analyzed. The various pharmacokinetic 
parameters such as peak plasma concentration (Cmax), time 
taken to reach Cmax (Tmax), and area-under-the plasma 
drug concentration over time curve were calculated on a 
Sigma Plot software (version 8.0, Sigma, St. Louis, MO). 
At the same time, selected organs (lungs, liver, spleen, and 
kidney) were excised, isolated, dried, weighed, and stored at 
-80ºC 28. In the bio-distribution study, the stored isolated 
organs were recovered from deep freezer and kept out-side 
for some time at room temperature. Each tissue weighed 
separately, minced into pieces, and homogenized by tissue 
homogenizer (WiseMix HG-15D, Dathan Scientific, New 
Delhi, India) in phosphate buffer. The homogenized tissues 
were deproteinized with acetonitrile, vortexed (Swirlex-
Vortex Shaker, Tarson Make) for 5 min, centrifuged at 5000g 
for 10 min at 4-8 ºC, kept in dark for 30 min and filtered. 
Supernatant was filtered through a membrane filter and 
used for the analysis of INH upon suitable dilution with 
mobile phase by HPLC technique and compared with 
calibration graphs (obtained by analyzing pooled blank 
plasma spiked with known drug amounts) to obtain the 
plasma drug concentration versus time profile 29. 
Stastical analysis: 
Results were reported as mean ± Standard Deviation (SD) 
for the different parameters assessed. Student’s t-tests and 
One-Way Analysis of Variance (ANOVA) were used to 
compare between the independent variables, for two groups 
and more than two sets of data, respectively. For this 
purpose, IBM Statistical Package for Social Sciences (IBM 
SPSS® Statistics-version 21) was used, and the difference 
was considered statistically significant when the calculated 
p-value was less than 0.05.  
RESULT AND DISCUSSION 
Preparation of carrier system: 
For preparation of chitosan ascorbate microsphere (CAMs) 
chitosan ascorbate solution were prepared by salification of 
chitosan in ascorbic acid then resulting solution formed in a 
stable condition. Solubilization of chitosan by ascorbic acid 
due to the reactive amino groups in chitosan chains can be 
protonated by ascorbic acid molecules and form a positively 
charged water-soluble solution (Fig 1) 30. The amount of 
chitosan conjugated with ascorbic acid was determined 
using ninhydrin method as a reagent to react with primary 
and secondary amine group in the polymer with various 
concentrations 31, 32. The percent degree of substitution was 
determined by comparing the slope obtained from standard 
D-glucosamine and chitosan and shown in Fig.2. 
Eventually, chitosan ascorbate microspheres (CAMs) were 
synthesized by modified ionic gelation method using STPP 
into an aqueous solution of chitosan ascorbate. Chitosan, a 
polycationic polysaccharide is insoluble in alkaline and 
neutral pH, but in acidic condition, protonated amine group 
of chitosan interacts with phosphate ions provided by STPP 
ion, either by intermolecular or intramolecular linkage 33-35. 
Particle size of microspheres formed majorly depends on the 
ascorbic acid concentration and degree of deacetylation. 
Chitosan with higher degree of deacetylation makes it 
susceptible to provides more number of effective binding 
sites for the ionic interaction with ample positive charge due 
to amino groups that protonated in the acidic environment 
36. Whereas the increment in the concentration of ascorbic 
acid  in which chitosan was dissolved also enhancing the 
ability of chitosan to form linkage with STPP anion hence 
microspheres decrease in particle size (Table 1). During 
optimizing the formulation, as we increased concentration of 
chitosan, the zeta potential increased due to the increase in 
the positive charge of the chitosan molecules. Higher 
chitosan concentration caused more unneutralized -NH3+ on 
the microspheres surface, which led to a strong electrostatic 
repulsion between particles 37. This confirms that the 
formation of microspheres greatly depends on the 
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concentration of free amine groups which increase the 
surface charge and zeta potential of the microspheres. In 
addition, when increasing the concentration of chitosan, the 
particle size increased in a linear manner with a correlation 
coefficient. The same result was obtained by several authors 
38.  
Increasing the concentration of STPP, reduced the zeta 
potential of micropsheres because at higher concentration, 
STPP brings more negatively charged phosphate ions which 
react with chitosan amino groups. Therefore, the positive 
surface charge of the microspheres decreases. In addition, 
the microspheres size increased when increasing STPP 
concentration. At low STPP concentrations (1%), the amount 
of TPP was not enough to fully crosslink chitosan chains, and 
the preparations remained transparent. Further increase in 
TPP concentration (5%) led to an increase in particle size 
and to a slightly opaque solution. At higher TPP 
concentration (10 %), very large and polydispersed particles 
were obtained. The same result was reported already 39 who 
observed physical states of chitosan-TPP microspheres 
being either suspension (below a certain TPP concentration 
which depends on chitosan concentration) or precipitation 
(above a certain TPP concentration) in the range of TPP 
concentrations tested.  However, optimized particle size was 
found to be increased to 4.10±1.58 µm upon mannosylation. 
The increase in particle size after conjugation with mannose 
and zeta potential turned invert (Table. 2) can be due to the 
surface anchoring of mannose moieties to the amine groups 
present on the surface of CAMs 19. 
 
Table 3:   Characteristic peaks of chitosan in IR spectrum 
Stretching/Bending vibration frequencies (cm-1) Functional Group and inference 
Characteristic peaks of chitosan in IR spectrum 
3417.5 Overlapping stretch vibrations of –NH2 and –OH 
groups 
1643 Peak for 1º amide-I and -C=O 
2923.6 The aliphatic C-H stretching vibration 
1383 Weak deformation vibration of C-CH3 
Characteristic peaks of Ascorbic acid in IR spectrum 
3000-3500 Absorption band OH 
1426 C-O 
1736 C=O 
3420, 3359, 3215 Four OH group 
Characteristic peak after interaction of chitosan and ascorbic acid during solubilisation 
3524 to 3214 four –OH groups at C6, C3, C5, C2 
1754 lactone C=O forming intramolecular H-bond 
1673 intermolecular H-bond 
3524 to 3214 four –OH groups at C6, C3, C5, C2 
 
Characterization 
Ascorbic acid solubilizes the chitosan because chitosan 
contains amino groups which are protonatable in the acidic 
media, whereas ascorbic acid contains acidic hydroxyl 
functionality, thus allowing the formation of a complex 
through ionic interaction. Interaction between chitosan 
polymer and ascorbic acid during solublization was 
investigated by FTIR study (Fig. 2 and Table 3). FTIR spectra 
of chitosan shows in Fig. 3(a),  a characteristic strong peak at 
3417.5 cm−1 was attributed to overlapping stretch vibrations 
of –NH2 and –OH groups and the peak for amide I (C=O) at 
1643.7 cm−1 was seen. The aliphatic C-H stretching vibration 
of the polymer backbone occurred at 2923.6 cm−1 40. The 
weak deformation vibration of C-CH3 appeared at 1383.8 
cm−1, indicating a higher degree of deacetylation of CS used 
in this experiment (Zhang et al. 2014). In FTIR ascorbic acid 
showed in Fig. 3(b) the four peaks from 3524 cm−1 to 3214 
cm−1 were attributed to the four -OH groups at four carbon 
atoms. The stretch vibration of lactone C=O forming 
intramolecular H-bond occurred at 1754.4 cm−1 and that of 
lactone C=O forming intermolecular H-bond occurred at 
1673.8 cm−1 41. This result suggested from Fig. 3(c) -
NH2 groups on the Chitosan chains were protonated by the 
H+ supplied by Ascorbic acid. The decrease of peak at 3428.2 
cm−1 in indicated the reduction of free –NH2 groups after 
solubilize the chitosan with ascorbic acid.  
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Figure 1: Interaction mechanism between A): Ascorbic acid B): chitosan polymer C): Final molecule Chitosan Ascorbate 
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Figure 2: Degree of substitution on chitosan molecule by ascorbic acid 
 
 
Figure 3: Comparative FTIR study of a). Chitosan, b). Ascorbic acid and c). After solubilisation 
 
To characterize the mannosylation on CAMs system, in the 
mannose ligand, aside of the broad O–H band in the 3391cm-
1 range, the minimum transmittance was in the 950–
1200cm−1 region where the C–O–C and C–O–H link band 
positions are found. The two shoulder peaks at 1064 and 
1324 cm−1 can be attributed to the glycosidic links of 
mannose 42. The characteristic wave numbers that can be 
used for the quantification of mannose, viz., 1157.5, 1294.8 
and 916.2 were present in mannosylated chitosan ascorbate 
microspheres. FTIR studies on mannosylated chitosan- 
displayed decreasing intensities with peak broadening for 
various bands of chitosan as well as of mannose, implying an 
interaction between these chemical moieties. This clearly 
confirmed the presence of mannose on m-CAMs carrier 
system (Fig. 4). 
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Figure 4: FTIR spectrum of (a) chitosan ascorbate microsphere (CAMs), (b) mannose ligand, (c) Mannosylated chitosan 
ascorbate (m-CAMs) 
Entrapment efficiency: 
The results confirmed the better entrapment efficiency of 
INH in both CAMs and m-CAMs. The possible reason may 
be the hydrophilicity of INH and being hydrophilic in nature 
polymeric matrix provided a safe home to hydrophilic INH. 
Further the lower drug entrapment in case of mannosylated 
carrier system as compare to plain, may possibly be due to 
the during mannosylation reaction that involves incubation 
in sodium acetate buffer (pH 4.0) for period of 24 h which 
might have led to leaching of drug in reaction medium. 
SEM Analysis: 
From the SEM photographic image it was observed that the 
optimized microspheres (CAMs and m-CAMs) were spherical 
in shape, they did not form agglomerations, and their 
surfaces were slightly smooth. The particle size obtained 
from SEM photography is close to the particle size obtained 
using the digital photographic microscope (Fig. 5). 
 
        
Figure 5: SEM image of a): chitosan microspheres (CAMs) b): mannosylated chitosan microspheres (m-CAMs) 
A): 
B): 
C): 
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PXRD: 
To determine the physical state of physical interaction of 
polymer and incorporation of drug to carrier system PXRD 
recorded of INH, blank CAMs, physical mixture of INH and 
CAMs, INH loaded CAMs and INH loaded m-CAMs and 
differactogram were shown in Fig. 6.  
Diffraction spectrum of INH showed distinct and high 
intensity peaks in the region of 2θ ranging from 15◦  to 25◦ . 
INH displays PXRD pattern with sharp and intense peaks, 
denoting a highly crystalline structure. The pattern matches 
that described in the literature 43 and no other peaks than 
those belonging to the INH crystalline phase were found.  
However, in case of INH-loaded CAMs, no such peaks could 
be observed. This could have occurred due to entrapment of 
drug within the microspheres. From these observations, we 
concluded that the drug was efficiently loaded within the 
microspheres and the amount of surface-adsorbed drug 
could be considered as negligible. The diffractograms of the 
INH loaded CAMs and m-CAMs for INH are shown the typical 
XRD peaks of both systems. When the drug was loaded into 
chitosan polymer in the form of microspheres the intensity 
of each peak markedly decreased. This is a sign of the drug(s) 
inclusion into both CAMs and m-CAMs formulations.  
In-vitro lung deposition study 
Removal of drug with delivery system and aerosolisation 
performance for carrier system was investigated using 
Andersen Cascade Impactor (ACI). The ACI is comprised of 
different plates or stages corresponding to the different 
regions of the respiratory system, from the oral cavity to 
alveoli. The particulate matter is drawn at a predetermined 
air-flow rate through the apparatus, resulting in deposition 
of the particles on different plates of ACI as a function of 
their particle size and aerodynamics.  
The ACI is similar to a twin stage impinger (TSI) in function. 
However in addition to particle size, it gives a detailed lung 
deposition data with additional parameters like %ED, MMAD 
and FPF. Mass Median Aerodynamic Diameter (MMAD) 
represents the average diameter below which 50% of the 
particles remain. The emitted dose (ED), i.e. the mass of drug 
deposited in the induction port, the stages and the filter, was 
expressed as the percentage (%ED) of the total recovered 
mass (i.e. from the induction port, the stages and the filter 
from the adapter, the inhaler and capsule) whereas FPF is 
generally regarded as the fraction of the total inhaled dose 
that reaches the stages corresponding to the cut-off diameter 
of 5 µm.  
The % ED values for all microspheres were high in the range 
from 85.1% to 89.6%, and this corresponds to minimal 
retention in the capsule and indicating that the microsphere 
powder was efficiently emitted from the Inhaler 46. MMAD 
value for microspheres were found (between 2-5 μm) 
satisfactory for delivery to the alveoli where the 
mycobacterium infection is mainly present (Fig. 7). 
 
Figure 6: Comparative PXRD of INH and various formulations
 
 
 
Figure 7: In-vitro lung deposition study  
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The lower MMAD and high FPF found with formulation of 
mannosylated carrier system that shown prepared 
formulation compatible with dry powder for inhalation. The 
%FPF depicted that the larger dose was available to the 
lungs after inhalation hence it help to target the formulation 
towards alveolar macrophage cells where the tubercular 
bacilli reside. 
In-vitro drug release:  
The release studies were carried out in two different 
simulated lung fluids as release medium, which is used to 
evaluate human exposure to particulates from 
environmental emissions. ALF is analogous to the fluid with 
which inhaled particles would come into contact after 
phagocytosis by alveolar and interstitial macrophages in the 
lung. Gamble’s solution represents the interstitial fluid deep 
within the lung.  
Cumulative In-vitro release profile of INH loaded CAMs and 
m-CAMs were presented in Fig. 8 (a and b).  At pH 7.4, INH 
loaded CAMs and m-CAMs formulations showed percent 
cumulative release of approximately 86% and 74% whereas 
at pH 4.5, 80% for INH loaded CAMs and 78% for m-CAMs, at 
the end of 72 h. The aqueous solubility of INH was high so 
the % cumulative release of INH from chiotsan microsphere 
is high and at acidic pH the swelling of polymer takes place 
which could enhance the drug(s) mobility and diffusion. It 
can be concluded that the developed formulations were able 
to release the drug in sustained manner in the 
phagolysosomal bio milieu. The release pattern of drug from 
both microsphere formulations followed a biphasic pattern, 
characterized by an initial burst, followed by a slower 
sustained release. The initial burst release may be due to the 
release of the drug present at or just beneath the surface of 
microspheres. Thereafter the release occurred due to the 
polymer erosion and diffusion of the drug molecules. The 
diffusion of drug(s) is through small pores and channels in 
the polymer matrix. Hence our carrier system releases drug 
inside Alveolar macrophage at late phagosomal phase of 
phagocytosis in controlled manner by erosion mechanism 
which may help in reduction in dosing frequency of drug, so 
this delivery system will be able to retain high amount of 
drug in the acidic pH and would be able to release more drug 
in the alveolar macrophages at the desired site of drug 47, 48. 
In vitro cell proliferation study: 
The cytotoxic effects of INH against A549 cells were 
examined by MTT assay. In the experiments, the cytotoxicity 
was evaluated by varying the concentration of free INH 
solution, drug loaded CAMs and m-CAMs. Cytotoxicity was 
observed to be INH concentration-dependent for all the 
tested samples (Fig. 9). The highest cytotoxic effects were 
found for free INH, which even in the lowest concentration 
(20 µl/mL) showed only a 55% cell viability that further 
decreased to 20% when the free drug was used in the 
highest concentration (100 µl/mL). These results show the 
high toxicity of INH that can cause side effects also when it is 
nebulized directly into the lung, where is the site of 
infection. The viability assay also showed that INH toxicity 
can be reduced by entrapped the drug in chitosan 
microspheres. Cell viability was generally not affected by 
chitosan concentration, in fact empty particles showed 
always the best results in term of viability. As can be seen in 
Fig. 9, the presence of mannosylation slightly decreased the 
viability of cells probably may be because of STPP was in the 
microspheres also after the purification steps. 
 
 
Figure 8: In-vitro Drug Release INH from formulation a): at 
pH 7.4 and b): at pH 4.5
 
 
Figure 9: Effect of CAMs and m-CAMs for cell viability by MTT on A549 cell lines 
0
20
40
60
80
100
0 20 40 60 80
C
u
m
u
la
ti
ve
 %
 d
ru
g 
re
le
as
e 
 
Time (h) 
CAMs
0
10
20
30
40
50
60
70
80
90
0 4 8 121620242832364044485256606468727680
C
u
m
u
la
ti
ve
 %
 D
ru
g 
re
le
as
e
 
Time (h) 
CAMs
0
20
40
60
80
100
20 40 60 80 100
%
 C
el
l V
ia
b
lil
it
y 
Concentration (µg/mL) 
Control CAMs m-CAMs
Bagre et al                                                                                                                     Journal of Drug Delivery & Therapeutics. 2019; 9(3):13-25 
ISSN: 2250-1177                                                                                  [22]                                                                                 CODEN (USA): JDDTAO 
Pharmacokinetics and Bio distribution: 
Various pharmacokinetic parameters such as Cmax (µg/ml), 
Tmax (h), and AUC 0–24 (µg h/ml) of the developed 
optimized microspheric formulation was determined and 
compared with the plain INH solution (Table: 6) and organ 
distribution of drug in various organs shown in Fig.10 (A-D). 
It was observed that peak plasma concentrations of the drug 
were achieved quickly in case of plain drug compared with 
the developed formulation. A significant higher Tmax and 
AUC in experimental formulation could be related to 
controlled and localized drug delivery under the 
physiological conditions. The higher values of AUC of 
developed formulations clearly indicated that drug 
concentrations were maintained within the 
pharmacologically effective range for longer period of time. 
From in vivo studies, it was observed that there was a 
significant increase in drug accumulation within the desired 
cellular tropics when they were administered in 
microspheric form (CAMs and m-CAMs) formulations. As 
expected, the plasma and organ distribution studies had 
shown higher amount of drug(s) recovery from lungs in the 
case of both the ligand conjugated formulations as compared 
to plain counterparts and free drug, indicating the efficacy of 
developed carrier for lung targeting of INH. 
 
 
A): In lungs 
 
B): In liver 
Figure 10(A): In vivo organ distribution of  INH administered as CAMs loaded and m-CAMs loaded as compare to plain 
solution (mean  ±SD, n=3). 
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C): In spleen 
 
D): In kidney 
Figure 10(B): In vivo organ distribution of  INH administered as CAMs loaded and m-CAMs loaded as compare to plain 
solution (mean  ±SD, n=3). 
Table 6: Pharmacokinetic parameters after pulmonary administration of free drug solution and microspheric formulations into 
Balb/c mice. 
Formulation Cmax Tmax AUC 0-24h (µg/ml/h) 
Free drug INH 5.55±1.21 2.03±0.74 32.47±5.14 
INH-CAMs 8.81±0.14 16.41±0.81 309.1±7.10 
INH-m-CAMs 9.21±1.74 19.48±0.44 331.24±1.1 
 
CONCLUSION 
Inhalable chitosan ascorbate microsphere were successfully 
prepared by salification of chitosan with ascorbic acid and 
then fabricated by ionic gelation method, hence the 
captivative antioxidative potential and non-toxic nature of 
carrier system in which first line antitubercular drug (INH) 
incorporated for treatment of pulmonary tuberculosis. The 
microsphere then further mannosylated to m-CAMs, so 
targetability of isoniazid to alveolar macrophages increased. 
The microsphere did not affect the viability of A549 cells 
during in-vitro condition. Overall, results obtained from 
various studies so far indicate a potential application of the 
proposed systems in pulmonary tuberculosis therapy. Hence 
this approach for delivery of isoniazid loaded 
mannospylated chitosan microspheres to alveolar 
macrophages has been successfully attempted.  
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